Clinical Trials Logo
  1. Home
  2. Acute Myeloblastic Leukemia
  3. NCT01307241

RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML

Acute Myeloblastic Leukemia Clinical Trial

Official title:
Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.

Clinical Trial Summary

Results of actual treatment in ALL are not optimal. New prognostic factors, which may determine clinical & molecular response are required. Hyper-CVAD is an internationally accepted schema for such patients. The objective of this pilot study is to evaluate polymorphisms regarding RFC (reduced folate carrier) and MTHFR enzyme, which may affect the function of these proteins, and therefore the intracellular bioavailability of methotrexate. Also, the expression levels of hENT1 and dCK will be evaluated, since such genes codify for citarabine intracellular transport and activation, respectively. Clinical characteristics will be tabulated and analyzed for responders & non-responders patients. Uni- & multivariate analysis will be done to evaluate factors influencing on response and survival.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01307241
Study type Observational
Source National Institute of Cancerología
Contact
Status Active, not recruiting
Phase N/A
Start date December 2010
Completion date December 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT01041040 - LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Phase 4
Completed NCT00552825 - Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children N/A
Recruiting NCT01966497 - Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia N/A
Active, not recruiting NCT01457885 - Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Phase 2
Completed NCT04082286 - Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia Phase 1
Completed NCT01611116 - Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia Phase 2
Completed NCT00504920 - Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients N/A
Completed NCT00354120 - Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant Phase 2/Phase 3
Completed NCT03280290 - Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft N/A
Completed NCT01435343 - Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia Phase 1/Phase 2
Completed NCT00487448 - SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Phase 4
Recruiting NCT05499611 - Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia
Completed NCT00390715 - Treatment of Acute Myeloblastic Leukemia in Younger Patients Phase 4
Completed NCT05696457 - Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT N/A
Recruiting NCT01296178 - PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years N/A
Completed NCT00435864 - Natural Killer Index From Hematopoietic Stem Cell Graft N/A